What Is Retatrutide? A Beginner's Research Guide
If you've followed the rapid evolution of GLP-1-class research peptides, you've likely come across retatrutide. It's one of the most talked-about compounds in metabolic research right now — and for good reason.
So what is retatrutide, and how does it differ from the better-known options already on the market? This guide breaks everything down in plain language.
What Is Retatrutide?
Retatrutide (also called LY3437943) is a synthetic research peptide developed by Eli Lilly. It is classified as a triple agonist — meaning it targets three hormone receptors simultaneously:
- GLP-1 (glucagon-like peptide-1) — a gut hormone that regulates insulin release and appetite
- GIP (glucose-dependent insulinotropic polypeptide) — another incretin hormone involved in insulin secretion and fat storage
- Glucagon receptor — involved in glucose regulation and energy expenditure
Most research peptides in this category target one or two receptors. Retatrutide's triple-agonist profile is what makes it scientifically distinct and why it has attracted significant attention from researchers.
See the retatrutide research profile and compare vendor prices on PeptidePrices.
How Does Retatrutide Work?
Understanding retatrutide means understanding what each receptor does when activated.
GLP-1 receptor activation slows gastric emptying (food leaving the stomach) and stimulates insulin secretion in a glucose-dependent manner. This combination reduces post-meal blood sugar spikes and suppresses appetite by acting on satiety centers in the brain.
GIP receptor activation amplifies the insulin response to meals and appears to modulate fat tissue directly. GIP receptors are found in adipose (fat) tissue, and activation may affect how the body handles fat storage and lipolysis (fat breakdown).
Glucagon receptor activation increases energy expenditure and promotes the liver to release glucose from stored glycogen — a mechanism that helps maintain metabolic rate even during caloric restriction.
The combination of all three pathways is what distinguishes retatrutide from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). By also activating the glucagon receptor, retatrutide adds an energy-expenditure component that the others don't have.
What Does the Research Say?
Retatrutide has been studied in Phase 2 clinical trials in humans — which makes it more advanced in the research pipeline than many of the research peptides in this space.
The TRIUMPH-1 Phase 2 trial (published in the New England Journal of Medicine in 2023) enrolled 338 adults with obesity. Participants receiving the highest dose (12 mg once weekly) achieved an average weight reduction of approximately 24% of body weight at 48 weeks — a result that exceeded any single agent studied at that point.
This is substantially higher than what has been observed with semaglutide (~15% with Wegovy) or tirzepatide (~22% with Zepbound) in their respective trials, though cross-trial comparisons have limitations.
Retatrutide is currently in Phase 3 trials. It has not received FDA approval as of this writing.
You can explore additional research citations in the PeptidePrices research database.
Retatrutide vs. Semaglutide vs. Tirzepatide
These three compounds are often compared because they all target incretin receptors. Here's a quick breakdown:
| Compound | Receptor Targets | Approval Status |
|---|---|---|
| Semaglutide | GLP-1 | FDA-approved (Ozempic, Wegovy) |
| Tirzepatide | GLP-1 + GIP | FDA-approved (Mounjaro, Zepbound) |
| Retatrutide | GLP-1 + GIP + Glucagon | Phase 3 trials (not approved) |
The additional glucagon receptor component in retatrutide is theorized to explain its outsized effect on body weight relative to the dual agonists. However, the glucagon activation also introduces additional complexity in terms of potential effects on liver glucose output and metabolic rate.
Retatrutide and Legality
Retatrutide is not FDA-approved and exists in a research-chemical gray area. In the United States, it is sold by research vendors labeled for in-vitro and research use only.
Legal status varies internationally. Some countries have stricter regulations on unapproved peptides than others.
Get the weekly peptide-pricing digest
Top 10 deals across 30+ vendors, sent every Monday. One email a week max. Unsubscribe anytime.
The Legal Status Map on PeptidePrices provides a country-by-country overview of research peptide regulations. Always review this before purchasing.
Comparing Retatrutide Prices
Because retatrutide is a more recently synthesized research peptide, pricing can vary widely across vendors. Synthesis complexity and vendor sourcing practices both affect price.
PeptidePrices normalizes prices per milligram across all tracked vendors, so you can make a fair comparison rather than being misled by different vial sizes.
See the live retatrutide price comparison across all vendors.
If you're building a research protocol that includes retatrutide alongside other metabolic peptides, the AI Stack Builder can help you think through combinations and estimate total research costs.
Frequently Asked Questions About Retatrutide
What is retatrutide used for in research?
Retatrutide is primarily studied in the context of metabolic health — specifically obesity, type 2 diabetes, and related cardiometabolic conditions. Its triple-agonist mechanism makes it a subject of interest for researchers studying energy balance.
Is retatrutide stronger than semaglutide?
Phase 2 data suggests retatrutide produces greater weight reduction than semaglutide in clinical trial settings. However, "stronger" is a simplification — the two compounds have different mechanisms and different side effect profiles. Direct head-to-head trials have not been completed.
Has retatrutide been approved by the FDA?
No. As of this writing, retatrutide is in Phase 3 clinical trials and has not received FDA approval. It is sold as a research chemical.
What makes retatrutide a triple agonist?
Retatrutide activates three receptors — GLP-1, GIP, and glucagon — simultaneously. Most other peptides in this class target one or two. The glucagon component is what primarily distinguishes it.
Is retatrutide legal to buy for research?
In the United States, research peptides sold for in-vitro and laboratory use exist in a regulatory gray area. They are not scheduled substances but are not approved drugs. Check the Legal Status Map for your country's specific regulations.
Where can I compare retatrutide vendor prices?
PeptidePrices tracks pricing across 19+ vendors with per-milligram normalization. See the retatrutide price comparison here.
Can retatrutide be combined with other peptides?
In research settings, retatrutide is often studied in isolation. If you're exploring multi-peptide protocols, the AI Stack Builder can help you think through options.
Wrapping Up
Retatrutide is one of the most scientifically significant research peptides in the metabolic space right now. Its triple-agonist profile produces effects that go beyond what single or dual agonists achieve in clinical data, though it remains unapproved and in active trials.
If you're researching retatrutide, the most important steps are understanding the mechanism, reviewing the published Phase 2 data, understanding the legal landscape, and comparing vendor prices before purchasing.
Compare retatrutide prices across all vendors at PeptidePrices — find the best price in seconds.
For research purposes only. Not for human consumption. Not medical advice. Always consult a qualified healthcare provider before making any health or supplementation decisions.
Was this useful? Get the next one in your inbox.
One peptide deep-dive a week, plus the top deals across 30+ vendors. No spam.